-
Mashup Score: 0HemeOncBuddy - 13 day(s) ago
Research in Hematology and Oncology has seen a remarkable growth with a significant amount of treatment advancements in recent years. Keeping up with recent literature has become more challenging. In the HemeOncBuddy app you can find the most important and practice-changing clinical trials in Hemato…
Source: apps.apple.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
PURPOSEThe open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non–small-cell lung cancer (mNSCLC)….POSEIDON: 1L tremelimumab + durvalumab + chemotherapy (CT) significantly improved PFS and OS versus CT in stage IV NSCLC.
Source: ascopubs.orgCategories: General Medicine NewsTweet-
POSEIDON trial Peters S et al, JTO, 2025, PMID: 39243945 https://t.co/zW78tO96gG Background: Phase III POSEIDON 5yr analysis, N=761 in metastatic NSCLC, any PD-L1 treated with first-line chemo with or without dual immunotherapy. Patients received platinum-based chemo ±
-
-
Mashup Score: 0
PURPOSEThe open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non–small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti–PD-(L)1, and targeted …EVOKE-01: primary analysis of sacituzumab govitecan v docetaxel in previously treated #NonSmallCellLungCancer #LCSM.
Source: ascopubs.orgCategories: General Medicine NewsTweet-
EVOKE-01 Trial Paz-Ares L et al., JCO 2024 https://t.co/mGKWRuVUy1 Background: Phase III EVOKE-01 trial, N≈486 in advanced NSCLC previously treated with immunotherapy and chemotherapy. Compared Trop-2 antibody-drug conjugate sacituzumab govitecan vs docetaxel. Arm A:
-
-
Mashup Score: 0
This randomized clinical trial examines the efficacy of ivonescimab plus chemotherapy vs chemotherapy alone for patients with advanced or metastatic non–small cell lung cancer with the epidermal growth factor receptor (EGFR) variant.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
HARMONi-A trial Fang W et al, JAMA, 2024, PMID:38764857 https://t.co/S67OcgA0rt Background: randomized clinical trial included 322 patients diagnosed with non–small cell lung cancer (NSCLC) with EGFR variant, advanced or metastatic stage (stage IIIB, IIIC, or IV), whose disease
-
-
Mashup Score: 0
Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent…
Source: www.nejm.orgCategories: General Medicine NewsTweet-
ADRIATIC trial Cheng Y et al, NJEM, 2024, PMID: 39268857 https://t.co/Yx3SWSsXGe Background: phase III RCT included 730 patients diagnosed with limited-stage small-cell lung cancer who had not progressed after concurrent platinum-based chemoradiotherapy, cCRT. Prophylactic
-
-
Mashup Score: 0Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung Cancer - 13 day(s) ago
This randomized clinical trial examines whether stereotactic body radiotherapy improves local control compared with hypofractionated conventional radiotherapy.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
LUSTRE trial Swaminath A et al., JAMA Oncol 2024 – PMID: 39298144 https://t.co/3SropCaphU Background: Phase III LUSTRE trial, N=203 in medically inoperable stage I NSCLC, comparing stereotactic body radiotherapy, SBRT vs hypofractionated conventional radiotherapy. LUSTRE
-
-
Mashup Score: 0Perioperative Nivolumab in Resectable Lung Cancer | NEJM - 13 day(s) ago
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj…
Source: www.nejm.orgCategories: General Medicine NewsTweet-
77T trial Cascone T et al, N Engl J Med, 2024, PMID: 38749033 https://t.co/J1xbL0Ujga Background: randomized clinical trial included 461 patients diagnosed with stage IIA to IIIB resectable non–small cell lung cancer (NSCLC), all patients were treatment-naive and eligible for
-
-
Mashup Score: 0
Osimertinib is a recommended treatment for advanced non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR-mutated N…
Source: www.nejm.orgCategories: General Medicine NewsTweet-
LAURA trial Lu S et al, NEJM, 2024, PMID: 38828946 https://t.co/2goO7d3lGd Background: phase III RCT included 216 patients diagnosed with unresectable stage III EGFR-mutated non–small-cell lung cancer, NSCLC Arm A: Osimertinib, 80 mg, PO, once daily until PD Arm B: Placebo
-
-
Mashup Score: 0
PURPOSEIn the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation, the role of anti–PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase III study evaluates the efficacy …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
ATTLAS trial Park S et al., JCO 2024 –, ATTLAS Trial, KCSG-LU19-04 https://t.co/e6YOXggcGJ Background: Phase III ATTLAS trial, N≈220 in advanced NSCLC with EGFR or ALK mutations after TKI failure. Evaluated adding immunotherapy/bevacizumab to chemotherapy. Arm A:
-
-
Mashup Score: 2Ali Dzhemiliev: Impressive talk by Nelya Melnitchouk at 20th-anniversary celebration of the CSPH - OncoDaily - 3 month(s) ago
Ali Dzhemiliev: Impressive talk by Nelya Melnitchouk at 20th-anniversary celebration of the CSPH / Ali Dzhemiliev, Brigham and Women’s Hospital, cancer,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Impressive talk by @NelyaMel at 20th-anniversary celebration of the CSPH - @AliDzhemiliev https://t.co/JchUZ9daL6 #Cancer…
-
Please give us a feed back! What other trials would you like to see? we are open to any suggestions! Again, you can find all summaries in the app, click here to download: https://t.co/jDSGMXomwO Learn more about our team here: https://t.co/fMFVpPtcb4